This trial is testing whether adding the immunotherapy drug pembrolizumab to standard radiation therapy improves outcomes for patients with head and neck squamous cell carcinoma.
1 Primary · 4 Secondary · Reporting Duration: 3 years
Active Control
Experimental Treatment
114 Total Participants · 2 Treatment Groups
Primary Treatment: Pembrolizumab · No Placebo Group · Phase 2
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: